Part 1: The Radiopharmaceutical Launch Playbook: What Pharma Must Get Right Beyond the Drug

What does it really take to successfully launch a radiopharmaceutical? In Part 1 of this special roundtable “Rx for Biotech” podcast series, Chris Leidli met with Dr. Babak Saboury and Dr. Eliot Siegel, founders of United Theranostics and nationally recognized leaders in nuclear oncology, to discuss one of the biggest challenges facing the radiopharmaceutical industry today: building the infrastructure to expand patient access to these innovative medicines. While radioligand therapies (RLTs) and theranostics are generating unprecedented excitement in oncology, many pharmaceutical companies underestimate the complexity of delivering these therapies to patients. In this episode, we discuss: • Why only a small percentage of eligible patients currently receive radioligand therapy • Site readiness, staffing, and infrastructure challenges • Why traditional pharmaceutical launch models often fail in radiopharmaceuticals • Building sustainable access for patients • What pharmaceutical companies should understand before launching an RLT This conversation offers a front-line perspective on what it will take to scale the future of radiopharmaceutical medicine. 🎧 Subscribe for more conversations on radiopharmaceuticals, precision medicine, oncology, targeted therapies, and advanced therapies. #Radiopharmaceuticals #RadioligandTherapy #Theranostics #PrecisionMedicine #Oncology #NuclearMedicine #Pharma #Biotech #HealthcareInnovation #RxForBiotech